Ryan Haumschild, PharmD, MS, MBA, CPEL

Panelists discuss the benefits of implementing bispecific therapy programs in the community setting as well as factors influencing the decision to administer these agents at an academic center vs a community setting.

Panelists discuss the factors considered when selecting between BTK inhibitors and venetoclax plus obinutuzumab for chronic lymphocytic leukemia (CLL), the considerations for choosing among acalabrutinib, zanubrutinib, and ibrutinib, and the role of cytotoxic chemotherapy in the treatment of CLL in the era of targeted therapies.

Panelists discuss best practices for successfully implementing a bispecifics program and overcoming logistical challenges.

Panelists discuss the most common logistical challenges encountered when implementing bispecific therapies in both academic and community settings.

Panelists provide an overview of the current first-line treatment options for chronic lymphocytic leukemia (CLL), discussing the role of BTK inhibitors and venetoclax plus obinutuzumab (CLL14), and explore the continued role of ibrutinib in the CLL treatment landscape.

Panelists discuss how step-up dosing protocols reduce cytokine release syndrome (CRS) risk in patients with high-risk disease and when modifications might be necessary as well as the incorporation of infection prevention strategies, including prophylactic antimicrobials, into management plans.

Panelists discuss key strategies for preventing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients receiving bispecific therapies for B-cell lymphomas.

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) may include issues related to access, cost, and patient adherence, and highlight the need for ongoing research and collaboration to optimize BTKi use and improve patient outcomes in both diseases.

Panelists discuss how real-world data on the incidence of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) compare with clinical trial findings as well as the most critical patient-related risk factors for developing these toxicities.

Panelists discuss how comparative data from matching-adjusted indirect comparison (MAIC) analyses guide treatment decisions between bispecific therapies and the insights from MAIC results comparing epcoritamab and glofitamab that may influence therapy selection.

Panelists discuss key factors in deciding between monotherapy and combination approaches for bispecific therapies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) as well as the potential for combination therapies to be more viable in certain B-cell lymphoma subtypes.

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic options, and explore how the integration of these therapies into current chronic lymphocytic leukemia (CLL) and MCL treatment guidelines could reshape management strategies, with consideration given to factors such as efficacy, safety, and patient access.

Panelists discuss how the sequencing of bispecific therapies in first-line vs later-line settings should be guided by factors such as disease stage, prior treatments, and patient-specific characteristics to optimize therapeutic outcomes.

Panelists discuss how several studies evaluating bispecific therapies in earlier lines of therapy for diffuse large B-cell lymphoma and follicular lymphoma suggest that patients with high-risk or relapsed/refractory disease are most likely to benefit from these treatments.

Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine + rituximab (ECHO), acalabrutinib + lenalidomide + rituximab (ALR), acalabrutinib + umbralisib + ublituximab (AU2), ibrutinib + rituximab (ENRICH), and zanubrutinib + rituximab (CHESS), are exploring novel combinations to improve treatment outcomes and address unmet clinical needs in MCL therapy.

Panelists discuss how emerging data on odronextamab in diffuse large B-cell lymphoma suggest its potential to play a significant role in therapy, with promising results that may position it alongside or as a superior option compared with currently approved bispecifics.

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi) trials in chronic lymphocytic leukemia (CLL) are addressing unmet needs by offering new treatment options that target treatment-naive patients, potentially improving outcomes and filling gaps in the current therapeutic landscape.

A panelist discusses how biosimilar adoption faces multiple barriers despite proven cost benefits, exploring strategies for improving uptake, best practices for interchangeability, experiences with adalimumab switching, and future optimization opportunities in healthcare systems.

Panelists discuss how exciting new data from ASH 2024 on bispecific therapies for B-cell lymphomas, including epcoritamab in diffuse large B-cell lymphoma, mosunetuzumab in follicular lymphoma, and odronextamab are shaping treatment algorithms by providing long-term follow-up data that could influence therapeutic strategies and patient management.

Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes for treatment-naive patients, with a focus on emerging Bruton tyrosine kinase inhibitor (BTKi) regimens such as acalabrutinib plus venetoclax, pirtobrutinib plus venetoclax, and zanubrutinib combinations.

Panelists express their gratitude for the informative discussion and share their final thoughts on the evolving landscape of menopause management and the potential impact of new therapies on improving patient outcomes.

Panelists discuss the importance of addressing sleep disturbances in menopause management, even in the absence of vasomotor symptoms (VMS), and explore how emerging research on elinzanetant could impact sleep quality and its links to mood disorders, cardiovascular disease, and Alzheimer disease, while also contemplating the potential shift in the treatment paradigm for VMS with the introduction of new neurokinin-targeted therapies as either standard of care or in combination with other treatments.

Panelists discuss the notable adverse events observed in the OASIS trials with elinzanetant and compare the safety profiles of elinzanetant and fezolinetant with those of traditional treatments for vasomotor symptoms (VMS).

Panelists discuss the methodologies of the OASIS 1, 2, and 3 trials that investigated elinzanetant, highlighting key findings regarding its efficacy in reducing the frequency and severity of vasomotor symptoms (VMS) compared with other treatments, as well as its impact on quality of life and the speed at which patients experienced symptom improvement.

Panelists discuss the methodologies of the SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 trials that supported the approval of fezolinetant for moderate to severe vasomotor symptoms (VMS) and examine the key safety and efficacy results derived from these studies.

Panelists discuss the role of neurokinin in the pathophysiology of vasomotor symptoms (VMS) and examine the mechanisms of action of novel nonhormonal agents such as fezolinetant and elinzanetant, highlighting the advantages of targeting neurokinin pathways over traditional hormonal treatments and their potential to address related menopause issues such as mood disturbances and sleep disorders.

Panelists discuss how to effectively integrate vasomotor symptom (VMS) treatment into comprehensive health management plans for women, taking into account the significant comorbidities associated with menopause, such as cardiovascular disease and osteoporosis.

Panelists discuss how to improve treatment rates for vasomotor symptoms (VMS) by identifying actionable steps, examining the influence of socioeconomic status on health care access, and proposing initiatives to ensure equitable care for all women experiencing menopause.

Panelists discuss how underlying factors, including patient resistance to conventional treatments and the stigma surrounding menopause, contribute to the persistent undertreatment of vasomotor symptoms (VMS), which can severely impact women’s quality of life and increase their risk for long-term health issues such as cardiovascular disease and Alzheimer disease.